2. Academic Validation
  3. High-Throughput Drug Screening in a Cellular Model of KRAS-Driven Arteriovenous Malformations

High-Throughput Drug Screening in a Cellular Model of KRAS-Driven Arteriovenous Malformations

  • J Invest Dermatol. 2025 Mar 22:S0022-202X(25)00330-6. doi: 10.1016/j.jid.2025.02.151.
Fanourios Michailidis 1,  Davide Zecchin 2,  Mohammad Rabii 1,  Ignacio Del Valle Torres 1,  Aimie Sauvadet 1,  Ming Jiang 3,  Michael Howell 3,  Dale Bryant 1,  Satyamaanasa Polubothu 4,  Veronica A Kinsler 5
Affiliations

Affiliations

  • 1 Mosaicism and Precision Medicine Laboratory, Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • 2 Institute of Ophthalmology, University College London, London, United Kingdom.
  • 3 High Throughput Screening Facility, Francis Crick Institute, London, United Kingdom.
  • 4 Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond Street Hospital for Children, London, United Kingdom.
  • 5 Mosaicism and Precision Medicine Laboratory, Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond Street Hospital for Children, London, United Kingdom. Electronic address: v.kinsler@ucl.ac.uk.
PMID: 40122156 DOI: 10.1016/j.jid.2025.02.151
Keywords

AVM; Mosaic disorders; Oncogene; Therapeutics; Vascular anomaly.

Figures
Products